Seaside has a biomarker effort to identify factors present in specific subsets of individuals with idiopathic ASD. The ultimate goal is to identify biomarkers that predict who will respond to each specific treatment.
Next Generation mGlur5 Negative Allosteric Modulator (NAM)
In collaboration with Vanderbilt University, Seaside Therapeutics is developing next generation mGluR5 NAMs for the treatment of neurodevelopmental disorders.
M1 Muscarinic Acetylcholine Receptor (M1) Modulator
Seaside Therapeutics is also working in collaboration with Vanderbilt University to develop the first selective M1 antagonist. Research indicates that, similar to the mGluR5 receptor, the M1 receptor is linked to excessive synaptic protein synthesis in patients with fragile X syndrome, autism, and other neurodevelopmental disorders. By inhibiting M1 activation, antagonists may provide therapeutic benefit in individuals with these disorders.